Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BRNS NASDAQ:IMRN NASDAQ:INMB NASDAQ:SNTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRNSBarinthus Biotherapeutics$1.35-1.5%$1.24$0.64▼$2.92$55.78M-0.71251,593 shs60,944 shsIMRNIMMURON$2.22+10.8%$5.04$1.50▼$2.87$14.60M0.7281,857 shs12,391 shsINMBINmune Bio$1.85-4.1%$2.09$1.71▼$11.64$51.31M1.04435,100 shs392,310 shsSNTISenti Biosciences$2.18-5.6%$1.54$1.26▼$16.94$60.43M2.04320,446 shs401,253 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRNSBarinthus Biotherapeutics-1.46%-7.53%+28.57%-9.86%+12.51%IMRNIMMURON+3.50%+2.78%+19.79%+28.41%+10.75%INMBINmune Bio-4.15%-6.57%-7.04%-23.55%-64.49%SNTISenti Biosciences-5.63%+14.74%+56.83%+11.79%-0.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBRNSBarinthus Biotherapeutics$1.35-1.5%$1.24$0.64▼$2.92$55.78M-0.71251,593 shs60,944 shsIMRNIMMURON$2.22+10.8%$5.04$1.50▼$2.87$14.60M0.7281,857 shs12,391 shsINMBINmune Bio$1.85-4.1%$2.09$1.71▼$11.64$51.31M1.04435,100 shs392,310 shsSNTISenti Biosciences$2.18-5.6%$1.54$1.26▼$16.94$60.43M2.04320,446 shs401,253 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBRNSBarinthus Biotherapeutics-1.46%-7.53%+28.57%-9.86%+12.51%IMRNIMMURON+3.50%+2.78%+19.79%+28.41%+10.75%INMBINmune Bio-4.15%-6.57%-7.04%-23.55%-64.49%SNTISenti Biosciences-5.63%+14.74%+56.83%+11.79%-0.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBRNSBarinthus Biotherapeutics 2.33Hold$3.00122.22% UpsideIMRNIMMURON 1.00SellN/AN/AINMBINmune Bio 2.38Hold$18.50900.00% UpsideSNTISenti Biosciences 2.50Moderate Buy$9.67343.43% UpsideCurrent Analyst Ratings BreakdownLatest IMRN, BRNS, SNTI, and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025BRNSBarinthus BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/14/2025IMRNIMMURONWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/14/2025SNTISenti BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.0010/8/2025IMRNIMMURONWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025INMBINmune BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025SNTISenti BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025BRNSBarinthus BiotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025IMRNIMMURONWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025INMBINmune BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SNTISenti BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/8/2025SNTISenti BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.00(Data available from 10/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBRNSBarinthus Biotherapeutics$14.97M3.67N/AN/A$3.23 per share0.42IMRNIMMURON$4.72M3.15N/AN/A$0.78 per share2.84INMBINmune Bio$10K4,917.30N/AN/A$1.45 per share1.28SNTISenti Biosciences$2.56M22.28N/AN/A$5.31 per share0.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBRNSBarinthus Biotherapeutics-$61.07M-$1.73N/AN/AN/AN/A-54.70%-44.75%11/5/2025 (Estimated)IMRNIMMURON-$3.38MN/A0.00N/AN/AN/AN/AN/AN/AINMBINmune Bio-$42.08M-$2.48N/AN/AN/AN/A-120.62%-92.94%10/30/2025 (Estimated)SNTISenti Biosciences-$52.79M-$8.95N/AN/AN/AN/A-223.98%-76.02%11/13/2025 (Estimated)Latest IMRN, BRNS, SNTI, and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025BRNSBarinthus Biotherapeutics-$0.45N/AN/AN/AN/AN/A10/30/2025Q3 2025INMBINmune Bio-$0.31N/AN/AN/AN/AN/A8/7/2025Q2 2025BRNSBarinthus Biotherapeutics-$0.29-$0.52-$0.23-$0.52N/AN/A8/7/2025Q2 2025INMBINmune Bio-$0.37-$0.34+$0.03-$1.05$0.00 millionN/A8/7/2025Q2 2025SNTISenti Biosciences-$0.58-$0.56+$0.02-$0.56$1.30 million$0.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/AIMRNIMMURONN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ASNTISenti BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBRNSBarinthus BiotherapeuticsN/A7.897.89IMRNIMMURONN/A5.104.19INMBINmune BioN/A4.204.20SNTISenti BiosciencesN/A3.263.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBRNSBarinthus Biotherapeutics25.20%IMRNIMMURON0.12%INMBINmune Bio12.72%SNTISenti Biosciences25.73%Insider OwnershipCompanyInsider OwnershipBRNSBarinthus Biotherapeutics10.70%IMRNIMMURON7.01%INMBINmune Bio35.70%SNTISenti Biosciences3.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBRNSBarinthus Biotherapeutics10740.72 million36.36 millionN/AIMRNIMMURONN/A6.71 million6.24 millionNot OptionableINMBINmune Bio1026.58 million17.09 millionOptionableSNTISenti Biosciences426.16 million25.34 millionNot OptionableIMRN, BRNS, SNTI, and INMB HeadlinesRecent News About These CompaniesSenti Bio to Present at Chardan's 9th Annual Genetic Medicines ConferenceOctober 16 at 9:05 AM | globenewswire.comWhat is HC Wainwright's Forecast for SNTI Q3 Earnings?October 16 at 6:52 AM | marketbeat.comHC Wainwright Initiates Coverage on Senti Biosciences (NASDAQ:SNTI)October 16 at 2:07 AM | americanbankingnews.comHC Wainwright & Co. Initiates Coverage of Senti Biosciences (SNTI) with Buy RecommendationOctober 14 at 3:52 PM | msn.comSenti Bio to Present at BioJapanOctober 6, 2025 | globenewswire.comSenti Bio to Present at the MedInvest Biotech & Pharma ConferenceSeptember 18, 2025 | globenewswire.comSenti Bio to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comSenti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTechAugust 14, 2025 | globenewswire.comSenti Biosciences Discusses Phase 2 Dose Selection for SENTI-202 in Virtual Investor SegmentAugust 12, 2025 | quiverquant.comQSenti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid LeukemiaAugust 12, 2025 | globenewswire.comSenti Biosciences, Inc.: Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML ...August 8, 2025 | finanznachrichten.deSenti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025August 7, 2025 | globenewswire.comSenti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid LeukemiaAugust 5, 2025 | globenewswire.comSenti Biosciences Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand ConferenceJuly 23, 2025 | finance.yahoo.comSenti Biosciences Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025 | globenewswire.comSenti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience ForumJuly 21, 2025 | globenewswire.comSenti Biosciences, Inc. Appoints Bryan Baum to Board of DirectorsJuly 18, 2025 | quiverquant.comQSenti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of DirectorsJuly 18, 2025 | globenewswire.comNASDAQ:SNTI Financials | Senti Biosciences Inc - Investing.comJuly 3, 2025 | investing.comSNTI - Senti Biosciences Inc Sustainability - MorningstarJuly 2, 2025 | morningstar.comMSenti Biosciences CEO Timothy Lu Highlights Advancements in Gene Circuit Technology at Nasdaq’s Amplify Spotlight SeriesJune 30, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMRN, BRNS, SNTI, and INMB Company DescriptionsBarinthus Biotherapeutics NASDAQ:BRNS$1.35 -0.02 (-1.46%) Closing price 10/16/2025 03:59 PM EasternExtended Trading$1.35 0.00 (0.00%) As of 10/16/2025 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.IMMURON NASDAQ:IMRNImmuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.INmune Bio NASDAQ:INMB$1.85 -0.08 (-4.15%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$1.86 +0.01 (+0.54%) As of 10/16/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Senti Biosciences NASDAQ:SNTI$2.18 -0.13 (-5.63%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$2.14 -0.04 (-1.83%) As of 10/16/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Buys Rival's Patent Treasure Trove in Strategic Move Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
